Trident Texofab [TTFL] vs Trident [TRIDENT] Detailed Stock Comparison
Trident Texofab
BSE
Loading...
Trident
NSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Trident Texofab wins in 5 metrics, Trident wins in 13 metrics, with 0 ties. Trident appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Trident Texofab | Trident | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 103.29 | 32.56 | Trident |
| Price-to-Book Ratio | 4.64 | 3.19 | Trident |
| Debt-to-Equity Ratio | 62.67 | 35.39 | Trident |
| PEG Ratio | N/A | 23.07 | N/A |
| EV/EBITDA | 44.92 | 15.79 | Trident |
| Profit Margin (TTM) | 2.06% | 6.27% | Trident |
| Operating Margin (TTM) | 2.47% | 11.49% | Trident |
| EBITDA Margin (TTM) | 2.47% | 11.49% | Trident |
| Return on Equity | 7.91% | 8.00% | Trident |
| Return on Assets (TTM) | 2.62% | 5.17% | Trident |
| Free Cash Flow (TTM) | $-137.08M | $7.15B | Trident |
| Dividend Yield | N/A | 1.66% | N/A |
| 1-Year Return | 384.01% | -26.93% | Trident Texofab |
| Price-to-Sales Ratio (TTM) | 2.64 | 2.03 | Trident |
| Enterprise Value | $2.46B | $153.02B | Trident |
| EV/Revenue Ratio | 2.01 | 2.20 | Trident Texofab |
| Gross Profit Margin (TTM) | 14.02% | 51.29% | Trident |
| Revenue per Share (TTM) | $116 | $14 | Trident Texofab |
| Earnings per Share (Diluted) | $2.08 | $0.85 | Trident Texofab |
| Beta (Stock Volatility) | -1.45 | -0.05 | Trident Texofab |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Trident Texofab vs Trident Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Trident Texofab | 0.73% | 0.35% | -0.39% | 12.43% | 30.09% | 25.24% |
| Trident | -1.28% | -4.22% | -14.28% | -0.50% | -6.77% | -18.25% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Trident Texofab | 384.01% | 79.12% | 414.00% | 397.34% | 397.34% | 397.34% |
| Trident | -26.93% | -26.38% | 313.13% | 573.48% | 1,205.66% | 798.70% |
Performance & Financial Health Analysis: Trident Texofab vs Trident
| Metric | TTFL | TRIDENT |
|---|---|---|
| Market Information | ||
| Market Cap | ₹3.22B | ₹141.14B |
| Market Cap Category | Small cap | Mid cap |
| 10 Day Avg. Volume | 6,700 | 8,625,133 |
| 90 Day Avg. Volume | 18,958 | 14,780,825 |
| Last Close | ₹214.85 | ₹27.68 |
| 52 Week Range | ₹42.01 - ₹220.00 | ₹23.11 - ₹40.20 |
| % from 52W High | -2.34% | -31.14% |
| All-Time High | ₹220.00 (Jun 23, 2025) | ₹70.35 (Jan 17, 2022) |
| % from All-Time High | -2.34% | -60.65% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.27% | -0.02% |
| Quarterly Earnings Growth | 0.27% | 0.90% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.06% |
| Operating Margin (TTM) | 0.02% | 0.11% |
| Return on Equity (TTM) | 0.08% | 0.08% |
| Debt to Equity (MRQ) | 62.67 | 35.39 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹46.27 | ₹8.67 |
| Cash per Share (MRQ) | ₹3.09 | ₹1.31 |
| Operating Cash Flow (TTM) | ₹-137,076,992 | ₹8.42B |
| Levered Free Cash Flow (TTM) | ₹-188,124,000 | ₹3.70B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.66% |
| Last 12-Month Dividend | ₹0.00 | ₹0.50 |
Valuation & Enterprise Metrics Analysis: Trident Texofab vs Trident
| Metric | TTFL | TRIDENT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 103.29 | 32.56 |
| Forward P/E | N/A | 23.07 |
| PEG Ratio | N/A | 23.07 |
| Price to Sales (TTM) | 2.64 | 2.03 |
| Price to Book (MRQ) | 4.64 | 3.19 |
| Market Capitalization | ||
| Market Capitalization | ₹3.22B | ₹141.14B |
| Enterprise Value | ₹2.46B | ₹153.02B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.01 | 2.20 |
| Enterprise to EBITDA | 44.92 | 15.79 |
| Risk & Other Metrics | ||
| Beta | -1.45 | -0.05 |
| Book Value per Share (MRQ) | ₹46.27 | ₹8.67 |
Financial Statements Comparison: Trident Texofab vs Trident
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TTFL | TRIDENT |
|---|---|---|
| Revenue/Sales | ₹382.06M | ₹18.64B |
| Cost of Goods Sold | ₹328.49M | ₹9.65B |
| Gross Profit | ₹53.58M | ₹8.99B |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹14.91M | ₹1.58B |
| EBITDA | ₹18.34M | ₹2.64B |
| Pre-Tax Income | ₹3.83M | ₹1.72B |
| Income Tax | ₹-1.27M | ₹382.90M |
| Net Income (Profit) | ₹5.10M | ₹1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TTFL | TRIDENT |
|---|---|---|
| Cash & Equivalents | ₹1.09M | ₹838.00M |
| Total Current Assets | ₹737.44M | ₹25.10B |
| Total Current Liabilities | ₹407.50M | ₹12.50B |
| Long-Term Debt | ₹102.71M | ₹10.15B |
| Total Shareholders Equity | ₹472.39M | ₹46.21B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹200.87M | ₹44.15B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TTFL | TRIDENT |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | TTFL | TRIDENT |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 6,700 | 8,625,133 |
| Average Daily Volume (90 Day) | 18,958 | 14,780,825 |
| Shares Outstanding | 13.56M | 5.08B |
| Float Shares | 5.51M | 1.20B |
| % Held by Insiders | 0.38% | 0.76% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Trident Texofab vs Trident
| Metric | TTFL | TRIDENT |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | ₹0.50 |
| Last 12-Month Dividend Yield | N/A | 1.66% |
| 3-Year Avg Annual Dividend | ₹0.00 | ₹0.53 |
| 3-Year Avg Dividend Yield | N/A | 1.15% |
| 3-Year Total Dividends | ₹0.00 | ₹1.58 |
| Ex-Dividend Date | N/A | May 27, 2025 |